FEMY — Femasys Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

Trend Edge Setup Score

Trend Edge rates FEMY Bearish with a Setup Score of 23, net conviction 21, actionability 26. How the Setup Score works →

Total Setup Score23
Directional BiasBearish
Net Conviction21
Actionability26 (in range)

Key signals behind this score

About Femasys Inc

Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for c… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$2.43
Market Cap$21.4M
Float7.3M
Shares Outstanding8.4M
Price/Sales (TTM)9.29
vs. Analyst Target+489.8% to analyst PT
Operating Margin (TTM)-1526.66%
Revenue (TTM)$2.3M
Dividend RateNone
Analyst Target Price$14.33 (4 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $1.0M -$6.9M $731,385 -$5.8M
2021 $1.2M -$7.5M $809,305 -$6.6M
2022 $1.2M -$11.4M $764,280 -$10.5M
2023 $1.1M -$14.2M $691,901 -$13.2M
2024 $1.6M -$18.8M $1.1M -$16.3M
2025 $2.3M -$18.6M $1.4M -$15.9M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Sep 2025 $729,394 -$4.2M
Dec 2025 $813,387 -$4.0M
Mar 2026 $424,889 $328,646
Jun 2026 $331,827 -$4.5M

Ownership & Float

Insider Ownership3.9%
Institutional Ownership47.3%
Short Float8.1%
% of All Funds Holding0.19%
Number of Funds Holding17

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$2.85Near-term / short-term trend
Weekly40-Week SMA$7.28Medium-term trend
Weekly80-Week SMA$12.28Cyclical trend (business cycle)
Weekly200-Week SMA$18.01Secular trend (multi-year)
Monthly10-Month SMA$7.00Near-term monthly trend
Monthly20-Month SMA$12.51Medium-term monthly trend
Monthly40-Month SMA$18.09Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Volume shelf data not available.

Historical Earnings Reactions (22 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -1.52% -1.54% 27.27% 4.27% -7.05%
1 Day -5.95% -7.17% 18.18% 10.97% -18.10%
1 Week -6.89% -7.51% 27.27% 30.13% -29.61%
2 Weeks -8.34% -8.63% 18.18% 49.78% -42.33%
1 Month -19.69% -20.83% 9.52% 2.15% -58.90%

Next earnings: November 2, 2026 (38 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -1.13% 33.3% 246
Tuesday 0.77% 41.4% 273
Wednesday -0.03% 43.5% 271
Thursday 0.27% 40.2% 264
Friday 0.52% 46.0% 265

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 47.3%

Insider Transactions — Smart Summary

Total insider ownership: 3.9%

Founder-led management: Kathy Lee-Sepsick (President and Chief Executive Officer)

12-Month Insider Activity Summary

Total Filings5
Net Value+$134,000
Net Shares Change41,875
% of Float0.6%
C-Suite Filings5
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Lee-Sepsick Kathy Chief Executive Officer +$50,000 1 1 buy
Elefant Dov Chief Financial Officer +$50,000 1 1 buy
Canning John Charles Chief Operating Officer +$14,000 1 1 buy
Sipos Jeremy Alexander Chief Technology Officer +$10,000 1 1 buy
Mifek Jeffrey Gerald Chief Clinical-Medical Affairs +$10,000 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-08-11 – 2026-08-11 5 5 +$134,000 5 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-08-11 Sipos Jeremy Alexander Chief Technology Officer +$10,000 Transaction at $3.20, now -24.1%
2026-08-11 Mifek Jeffrey Gerald Chief Clinical-Medical Affairs +$10,000 Transaction at $3.20, now -24.1%
2026-08-11 Lee-Sepsick Kathy Chief Executive Officer +$50,000 Transaction at $3.20, now -24.1%
2026-08-11 Elefant Dov Chief Financial Officer +$50,000 Transaction at $3.20, now -24.1%
2026-08-11 Canning John Charles Chief Operating Officer +$14,000 Transaction at $3.20, now -24.1%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Femasys Inc (FEMY) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for FEMY on Trend Edge →